#AgomabTherapeutics raises $89M Series D, led by Sanofi and #Invus. This funding supports Phase 2a trials for a #Crohn’s drug and early-stage studies for idiopathic pulmonary fibrosis and liver cirrhosis treatments. Key data expected in 2025. #Biotech#Fibrosis $SNY
Ocuphire Pharma merges with Opus Genetics to focus on gene therapies for inherited retinal diseases. The new company, Opus Genetics, will trade under the ticker "IRD" from Oct. 24. Exciting clinical milestones ahead in 2025! #Biotech#GeneTherapy#Ophthalmology $OCUP
@AmnealPharma receives FDA approval for Pyridostigmine Bromide Extended-Release Tablets, a once-daily treatment for soman nerve agent pretreatment. Developed using GRANDE® technology, it supports U.S. Armed Services with improved drug compliance. #FDA#Amneal#Pharma
12-year-old Kendric Cromer just became the first to receive FDA-approved gene therapy for sickle cell. After 44 days in the hospital, he's on a new path, free from the disease. His story is a milestone for those affected by sickle cell. #SickleCell#GeneTherapy
This Week at FDA: Key Updates
New #FDA guidances on #cancer patient-reported outcomes (PROs) and neurodevelopmental safety studies.
#HHS reports Baxter has resumed product supplies after #Hurricane#helene2024
Gilead to withdraw Trodelvy after confirmatory trial failure, while #Astellas’ Vyloy receives approval for HER2-negative gastric cancer.
FDA's #ARC program shares 2024 rare disease initiatives.
The FDA has approved @Astellas' Vyloy for treating gastroesophageal junction cancer. Approved in Japan and the UK earlier this year, Vyloy is used with chemotherapy for advanced or unresectable cases. #FDA#Astellas#Cancer#Vyloy#GastricCancer#Pharma#TYO
The FDA has delayed decisions on full approval for @Amgen's Lumakras (colorectal cancer) and Intercept's Ocaliva (PBC). Both drugs face scrutiny after mixed data and negative advisory committee votes. #FDA#Amgen#Lumakras#Intercept#Ocaliva#Pharma $AMGN
Earlier this month, Kezar Life Sciences announced that the mid-stage test of zetomipzomib in lupus nephritis had been placed on an @US_FDA clinical hold. Now, that program is being terminated.
#FDA#lupus#pharma#biospace
https://t.co/qIIAbXR9xk
🚀 @immusoft 's ISP-001, an engineered B cell therapy for mucopolysaccharidosis type I (#MPSI), shows promising results in a Phase I trial. Significant improvements in quality of life and no adverse effects reported nine months post-treatment! 🌟
Novartis pays China's Baiyu $70M upfront, with $1.1B chaser, for small molecule cancer candidate
#smallmolecules#Oncology#Biotech#Deals
https://t.co/lni8CPEDT8